5 Comments
Jun 30, 2022Liked by Richard Cheverton

Data from placebo group was lost, so the FDA says "I guess it will have to come from real-world effectiveness". Oh well. No data - no big deal. Watch the video here:

https://rumble.com/v1a6lxs-whoopsie-the-fda-green-lighted-the-moderna-jab-for-babies-after-losing-the-.html

Expand full comment
Jun 24, 2022Liked by Richard Cheverton

Agree. The data behind vaccination of the very young is weak. [http://medrxiv.org/lookup/doi/10.1101/2022.02.25.22271454]. All they have been able to demonstrate is the induction of antibodies. No survival benefit data. In fact the study is incredibly poorly done, with massive dropout to the last timepoint [https://www.fda.gov/media/159195/download]. You are correct that the vaccines were developed against a strain of SARS-CoV2 that is not in circulation now. The omicron variants have the E484K/Q and L452R mutations which greatly lessens the benefit of humoral immunity. Clinical trials also show that vaccination against the BA.1 and BA.2 variants are short-lived. Very soon, BA.4 and BA.5 will be dominant. In fact, people have revealed that mutations are occurring so fast, the clinical trials are impractical now, and Pfizer is now resorting to what Fauci calls "alternate pathways of decision making". [https://tobyrogers.substack.com/p/weird-that-the-i-believe-the-sciencetm]. Then there's the conflict of interest of the panel approving the vaccines not disclosing royalties they receive (due to a Bayh-Dole act loophole [https://www.washingtonexaminer.com/news/rand-paul-confronts-covid-infected-fauci-royalty-payments]).

For those who haven't read it yet, check this out:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062939/

Expand full comment